Pavankumar R

Spearheaded data-driven initiatives for whole entity, leveraging advanced analytics to inform strategic decision-making.

• Successfully established robust data lake to centralize and manage diverse data of healthcare platform business to deliver analytics use cases.
• Led the effort to standardize and harmonize disparate clinical data into SNOMED CT & ICD 10 for seamless analysis and deliver fraud rule based recommendation system.
• Led creation and deployment of Corporate Admin Employee Health Monitoring Module, which is integral part of main corporate client offerings.
• Delivered customized conversion funnels and journey optimization suggestions to product owners, aided business team in optimizing network areas relevant to platform offering.

1 year stint based programme to build competencies of Enterprise Risk Management, Data governance, Compliance, Data privacy and Cyber security.

• Entity level emerging risk identification resulted from COVID19 pandemic & controls adequacy monitoring.
• Risk Assessment & Prediction - GMP regulatory observations trends and Drug Price Control Order (NLEM - 2013 & 2015) impact & risk posed on India Portfolio.
• Digital transition projects identification for IA & SOX function through outside in best practices evaluation.

Process optimization, scale-up and technology transfer of differentiated drug products for emerging markets.

• Received certificate of appreciation for demonstrating exceptional ownership in rolling out “EMID-18” & “EMID-19”(Market: India) products to phase 2 clinical trials through seamless process development and GMP batches execution.
• Received certificate of excellence for achieving successful commercial scale up and on time process validation of top selling brand “Ketoexpress, Market: Russia”, demonstrating strong scientific acumen and planning capabilities.

Cross-contamination coordinator and Product manager for robustness enhancement of commercial products.

• Received MS & T start cap for Facilitating manufacturing of hormonal products in general manufacturing area in FTO 9 through scientific risk map, which led to ANVISA approval.
• Achieved increased process output of flagship product “Azacitidine for injection” through unique multi-lot approach to avoid dependency on CMO.
• Functioned as audit forerunner and was part of technical team responsible for clearance of US FDA warning letter for FTO 7 and other major audits.

Responsible for quality systems implementation and smooth technology absorption of products from R&D center/other mfg sites.

• Established best practices through harmonization of SOPs in line with Mylan global procedures.
• Being campus hired technical trainee, exposed to all major functions like quality, production and engineering of pharmaceutical manufacturing.